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Objectives: The objectives were to identify and compare the incidence of uterine perforation and other medically adverse events associated
with levonorgestrel-releasing intrauterine systems (LNG-IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) under
routine conditions of use in a study population representative of typical users.
Methods and materials: This is a multinational, prospective, non-interventional cohort study with new users of LNG-IUSs and copper
IUDs. In addition to a baseline questionnaire, women and their treating health care professional completed a single follow-up questionnaire
after 12 months. All patient-reported outcomes were validated by the treating physicians.
Results: A total of 61,448 women in six European countries were followed between 2006 and 2013 for more than 68,000 women-years of
observation (70% LNG, 30% copper devices). Overall, 81 uterine perforations were reported: 61 for LNG-IUSs [1.4 per 1000 insertions
(95% confidence interval {CI}: 1.1–1.8)] and 20 for copper IUDs [1.1 per 1000 insertions (95% CI: 0.7–1.7)], for an adjusted risk ratio
(RRadj) of 1.6 (95% CI: 1.0–2.7) when adjusted for age, body mass index, breastfeeding at time of insertion and parity. Breastfeeding at
time of insertion was associated with a sixfold increase (RR 6.1, 95% CI: 3.9–9.6), with no differences between LNG and copper IUD
users. Sixty-three of the total 81 perforations were associated with previously suspected risk factors (e.g., breastfeeding, time since last
delivery ≤36 weeks). No perforations led to serious illness or to injury of intra-abdominal or pelvic structures.
Conclusions: Uterine perforation incidence in this study was low, with a benign clinical course thereafter. The LNG-IUSs and copper IUDs
did not have clinically important differences in perforation rates.
Implications: The European Active Surveillance Study on Intrauterine Devices is the first large-scale, prospective, noninterventional study
to compare the perforation risk in LNG-IUS and copper IUD users. It is the first to examine the independent roles that breastfeeding
status and postpartum status have on perforation risk. Conducted during routine clinical practice, the findings are generalizable to
broader populations.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Keywords: Intrauterine device; Levonorgestrel; Copper; Uterine perforation1. Introduction
Uterine perforation is a potentially serious complication
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licenses/by-nc-nd/4.0/).from 0.3 to 2.6 per 1000 insertions for levonorgestrel-
releasing intrauterine systems (LNG-IUSs) (releasing 20
mcg LNG daily) and 0.3 to 2.2 for copper IUDs [1–6].
Extensive clinical experience with LNG-IUSs suggests that
serious outcomes such as peritonitis caused by perforation of
the uterine wall after insertion are rare; however, results from
large prospective studies with defined diagnostic follow-up
procedures are not available. Scientific evidence for the
safety of other IUDs — almost exclusively copper IUDs —
is also unsatisfactory and not necessarily generalizable to a
population of LNG-releasing IUD users.ess article under the CC BY-NC-ND license (http://creativecommons.org/
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described. Breastfeeding [5,7] and postpartum state [1,8] have
been associated with an increased perforation risk, but these
risk factors have previously not been examined independently
of each other. Other risk factors include lack of experience of
the healthcare professional (HCP) performing the insertion
[6,8,9], multiparity [7], nulliparity [1,9] and history of cesarean
delivery [1]. These findings, however, are not consistent across
studies. The European Active Surveillance Study on Intra-
uterine Devices (EURAS IUD) aimed to compare the uterine
perforation risk in users of LNG- and copper IUDs in routine
clinical practice.2. Methods
2.1. Study design
EURAS IUD was a prospective cohort study with
recruitment in six European countries from 2006 to 2012. Its
two cohorts consisted of new users of levonorgestrel-releasing
IUDs (releasing 20 mcg LNG daily) and all copper IUDs
currently used in the participating countries. A non-interference
approach was chosen to avoid influencing the health care
professionals’ prescribing behavior and to provide standard-
ized, comprehensive and reliable information on these IUDs
under routine medical conditions. The study was approved by
the ethical committee of the physicians' association in Berlin,
Germany, and the Ethics Committee of Hospital District of
Southwest Finland.
2.2. Study objectives
The primary outcome of interest was the incidence of
uterine perforation. This included an estimate of the
perforation incidence associated with IUD insertion, the
proportion of uterine perforations associated with serious
clinical complications, the interval between IUD insertion
and diagnosis of uterine perforation and the impact of
postpartum IUD insertion on the uterine perforation rate. For
each of these outcome measures, comparisons were made
between LNG and copper IUDs. For the analysis, the most
conservative approach was used to define perforation. All
events reported by the participating HCPs and/or patients
where any part of the device was considered to have crossed
the endometrium and entered the myometrium were
considered a perforation.
The secondary objective of this study was to compare the
contraceptive effectiveness and pregnancy-related outcomes
(including ectopic pregnancies) for users of LNG and copper
IUDs, and also the incidence of othermedically relevant adverse
events. This report focuses on only the primary objective; the
secondary outcome will be described in another report.
2.3. Study population
Study participants were recruited via a network of 1200
HCPs (e.g., gynecologists, midwifes, specialized clinics)who regularly insert IUDs. All women with a newly inserted
IUD were eligible for enrollment. Study participants
consisted of first-ever IUD users and consecutive users
(previous IUD use). After a patient decided to use an IUD,
participating HCPs invited the patient to participate in the
study. Because of the non-interference approach, eligibility
criteria were minimal: these included a willingness to sign an
informed consent form and data privacy form, and an
absence of a language barrier that could prevent the patient
from completing the questionnaires.
2.4. Baseline and follow-up questionnaires
At the time of IUD insertion, study participants completed a
baseline questionnaire designed to collect information relating
to their medical and gynecological history (including
medication and contraceptive use), age, body mass index
(BMI), lifestyle factors (smoking, alcohol consumption,
exercise, heavy lifting) and level of education. Breastfeeding
status and time since last delivery were of particular interest.
On a separate form, the women provided their contact details
(postal and email addresses and telephone numbers) and those
of an additional contact, such as a relative or friend, and also
those of their gynecologist or primary care physician. Contact
data were documented separately in compliance with data
protection regulations.
The follow-up questionnaire was sent to study participants
12 months after the IUD insertion. It contained questions
about the insertion procedure, its aftermath, complications,
medical checkups, illnesses, hospitalization and pregnancy,
along with changes in physician contact information.
All patient-reported events of interest were validated by
direct contact with the study participants and the diagnosing
and/or treating physicians. Participating HCPs followed their
participating patients in accordance with customary proce-
dures for newly inserted IUDs. To capture information
relating to the routinely conducted post-insertion examina-
tion during the first year, follow-up questionnaires were sent
1 year after insertion to the clinician. The clinician was asked
to record information on checkup dates, IUD position,
diagnosed perforations and patients’ medical conditions for
those patients who had returned to the respective clinician
during the first year post-insertion. The clinician was not
required to actively follow-up patients who did not come
back for a postinsertion checkup.
In order to minimize loss to follow-up, a multifaceted, four-
level follow-up process was used. The first level consists of
mailing the follow-up questionnaire, as well as two reminder
letters in case of no response. If these actions did not reinstate
contact with the women, multiple level 2 attempts are made to
contact the women by phone or, if necessary, their friends/
relatives who were listed as additional contacts, in addition to
the gynecologists/primary care physicians. Parallel level 3
activities consist of searches in national and international
telephone and address directories. If they are not successful, an
official address search via the respective governmental
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information on new addresses (or emigration or death).
2.5. Study size and evaluation
The study was powered to test noninferiority of LNG-
IUSs regarding the perforation risk in comparison to copper
IUDs. The null hypothesis to be tested was: risk ratio
(RR)Perf≥2 (i.e., the perforation incidence ratio for LNG-
IUD vs. copper IUD is higher than or equal to 2). The
alternative hypothesis was: RRPerfb2. Sample size calcula-
tions for a two-group test of equivalence in proportions
showed that a total of approximately 60,000 insertions would
be needed. These calculations were based on a perforation
rate of 0.5 per 1000 insertions, a 1-to-1 ratio between LNG
and copper IUD users, a one-sided α of 0.025 and a power of
0.80.
Crude as well as adjusted relative risks were calculated
using a logistic regression model. The appropriate con-
founding variables (see Section 3.2.) were included in the
model. Based on the expectation of a small absolute number
of perforations, the number of confounding variables was
limited to a small number of predefined risk factors as
recommended by the independent Safety Monitoring and
Advisory Council. In addition, a sensitivity analysis wasTable 1
Baseline characteristics of the study population by cohorts
Baseline characteristics LNG IUS
%
Age (years)
b20 0.9
20–29 15.9
30–39 39.6
40–49 40.9
≥50 2.7
BMI b20 5.7
BMI≥20 & b25 46.8
BMI≥25 & b30 30.1
BMI≥30 & b35 11.1
BMI≥35 6.1
Current smoker 23.2
Heavy smoker (N15 cigarettes per day) 4.0
Ex-smoker 21.0
Low (no university entrance level) 48.7
Mid (university entrance level) 23.0
High (university) 26.7
Ever cesarean delivery 19.6
Cesarean delivery at most recent pregnancy 14.3
Ever pregnant 93.0
Delivery 36 weeks or less before IUD insertion 17.3
Delivery 1 year or less before IUD insertion 19.8
Currently breastfeeding 9.2
Ever hormonal contraception use 91.8
Self-reported history of
Inflammation of ovaries/fallopian tubes 3.0
Endometriosis 2.2
Benign uterus tumor 6.8
Inflammation of intestine 1.8performed with other potential baseline risk factors to check
the appropriateness and robustness of the primary analysis. A
backward stepwise approach was used in which all
prognostic factors that did not change the point estimate of
the RR by more than 10% or that had no statistically
significant impact (pN0.10) were removed. This approach
was taken solely for exploratory reasons. All analyses were
performed using STATA 11.0 and SAS 9.1. This report
complies with the Strengthening the Reporting of Observa-
tional Studies in Epidemiology guidelines for observational
studies [10].3. Results
Recruitment started in Germany and Austria in 2006, the
United Kingdom and Finland in 2008, Sweden in early 2009
and Poland in November 2009. Recruitment stopped at the
end of 2012.
A total of 63,194 women at 1230 study centers agreed to
participate in the study. Overall, 1746 (2.8%) were excluded
because of protocol violations (e.g., no newly inserted IUD,
age under 18 years, no informed consent, duplication). The
remaining 61,448 quality-controlled computerized data sets
(one per woman) with baseline information were analyzed.Copper IUD
95% CI % 95% CI
(0.8–1.0) 2.0 (1.8–2.2)
(15.5–16.2) 32.0 (31.3–32.7)
(39.1–40.0) 42.4 (41.7–43.1)
(40.5–41.4) 22.7 (22.1–23.3)
(2.5–2.9) 0.9 (0.8–1.0)
(5.5–5.9) 6.9 (6.6–7.3)
(46.3–47.2) 49.5 (48.7–50.2)
(29.7–30.6) 28.3 (27.6–28.9)
(10.8–11.4) 10.2 (9.8–10.7)
(5.9–6.3) 4.8 (4.5–5.1)
(22.9–23.6) 24.2 (23.6–24.8)
(3.8–4.1) 4.0 (3.7–4.2)
(20.6–21.4) 18.8 (18.2–19.4)
(48.2–49.2) 41.6 (40.9–42.3)
(22.6–23.4) 26.0 (25.4–26.6)
(26.2–27.1) 29.6 (28.9–30.2)
(19.2–20.0) 17.6 (17.0–18.1)
(13.9–14.6) 12.9 (12.4–13.4)
(92.7–93.2) 88.0 (87.5–88.4)
(16.9–17.6) 24.7 (24.1–25.4)
(19.5-20.2) 28.7 (28.1-29.4)
(8.9–9.5) 14.6 (14.1–15.1)
(91.6–92.1) 81.6 (81.0–82.2)
(2.8–3.2) 2.2 (2.0–2.4)
(2.1–2.4) 0.7 (0.6–0.8)
(6.6–7.1) 2.8 (2.6–3.1)
(1.7–1.9) 1.3 (1.1–1.5)
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study entry, 43,078 women received an LNG-IUS (70.1%);
and 18,370, a copper IUD (29.9%). More than 30 types of
copper IUDswere included in the copper IUD cohort, the most
frequent ones being NovaT (200 or 380) with 37%, T Safe Cu
380 with 18% and Multiload CU (250 or 375) with 14%. The
percentage of first-time users was 46.3% and 52.0% for LNG
and copper, respectively.
Validated follow-up information was collected on 60,213
women: 42,353 users of LNG-IUSs and 17,860 users of
copper IUDs who contributed 68,372 women-years of
observation. In total, 1235 women, or 2.0% (1.7% for LNG-
IUS, 2.8% for copper IUD), were lost to follow-up during the
1-year follow-up period.
3.1. Baseline characteristics
The LNG-IUD cohort had a higher mean age (37.4 years)
than the copper IUD cohort (33.3 years) and contained a
higher proportion of women over the age of 40 (Table 1). For
example, LNG-IUS users were less likely than copper IUD
users to have never been pregnant (7.0% and 12.0%,
respectively) and to have delivered in the 12 months before
insertion (19.8% and 28.7%, respectively). The age difference
between the cohorts also partially explains the smaller
percentage of LNG-IUS users (9.2%) who were breastfeeding
at the time of insertion in comparison to copper IUD
users (14.6%).
3.2. Follow-up data
Overall, 81 perforations were identified during the 1-year
follow-up after insertion, of which 61 occurred during LNG-
IUS use and 20 during copper IUD use. Eighty percent of
these perforations were complete perforations. The propor-
tion per 1000 insertions was 1.4 [95% confidence interval
(CI): 1.1–1.8] for LNG-IUSs and 1.1 (95% CI: 0.7–1.7) for
copper IUDs. The crude relative risk for LNG-IUSs versus
copper IUDs was 1.3 (95% CI: 0.8–2.2).
A model containing the predefined prognostic factors of
age, BMI, breastfeeding at time of insertion and parity
(referred to as ‘Model 1’) yielded an adjusted RR of 1.6 (95%
CI: 1.0–2.7). A second model containing the variables age,
BMI, time since last delivery and HCP experience (referred
to as ‘Model 2’) did not substantially change the RR (1.7;
95% CI: 1.0–2.8). Therefore, a twofold higher risk of uterine
perforation with LNG-IUS use compared to copper IUD use
cannot be excluded. Alternative analyses using a backward
stepwise procedure to select prognostic factors yielded
almost identical results.
Only a small proportion of the perforations in both
cohorts (9% of LNG-IUS and 20% of copper IUD
perforation cases) were diagnosed during or immediately
after insertion; most perforations were reported only at
follow-up. The perforation risk was significantly higher in
women who were using an IUD for the first time compared
to women who had used an IUD previously. After adjustingfor time since last delivery and breastfeeding status at time of
insertion, the higher risk among first-ever users remained
statistically significant (hazard ratio: 2.6; 95% CI: 1.5–4.4).
3.3. Breastfeeding/time since last delivery
Thirty-five of the total 81 perforations occurred in women
who were breastfeeding: the incidence was 6.3 (95% CI: 4.1–
9.3) for LNG-IUSs and 3.7 (95%CI: 1.8–6.8) for copper IUDs
per 1000 insertions among breastfeeding women. The
incidence in parous women who were not breastfeeding was
1.0 (95% CI: 0.7–1.4) for LNG-IUSs and 0.5 (95% CI: 0.2–
1.0) for copper IUDs (Fig. 1). The relative perforation risk for
women breastfeeding versus not breastfeeding was 6.1 (95%
CI: 3.9–9.6); the respective relative risks for LNG-IUS and
copper IUD users were 6.3 (95% CI: 3.8–10.5) and 7.8 (95%
CI: 2.8–21.4).
Women who were breastfeeding at the time of insertion
were also more likely to have delivered in closer temporal
proximity to IUD insertion. Therefore, further stratified
analyses using time intervals of ≤36 weeks and N36 weeks
were conducted to assess the independent effects of these
factors on perforation risk (Table 2). The decision to
dichotomize the data at 36 weeks since delivery was made
following inspection of the data and was not governed by
clinical guidelines or a priori hypotheses.
Among breastfeeding women, the perforation incidence
was 5.6 (95%CI: 3.9–7.9) and 1.6 (95%CI: 0.0–9.1) per 1000
womenwho had delivered≤36 weeks and N36 weeks prior to
insertion, respectively. Among women who were not
breastfeeding at the time of insertion, the corresponding
figures were 1.7 (95%CI: 0.8–3.1) and 0.7 (95%CI: 0.5–1.1),
respectively, for the two interval strata (≤36 and N36 weeks).
Breastfeeding and time since last delivery were indepen-
dently associated with perforation risk. In summary, risk
estimates showed an important increase for breastfeeding
versus non-breastfeeding women at ≤36 weeks since last
delivery and for non-breastfeeding women at ≤36 weeks
versus N36 weeks since last delivery.3.4. Other prognostic factors
A stratified analysis was performed to assess potential
differences in perforation risk for patients with clinicians
who inserted fewer than 50 IUDs per year versus those who
inserted 50 or more IUDs per year for each user cohort. The
results suggest that patients of more experienced clinicians
were less likely to suffer perforation, regardless of IUD type
(Table 3). Other potential confounding variables such as
dilatation and the use of anesthesia were assessed in
univariate analyses, but no significant associations with
perforation risk were identified. In both cohorts, the RRs
comparing users with and without previous cesarean sections
(ever and at last delivery) were neither statistically
significantly decreased nor increased (data not shown).
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For both cohorts, more than 50% of perforations were
diagnosed within the first 2 months of IUD insertion. The
time interval between insertion and diagnosis did not differ
substantially between cohorts.
In most cases of perforation in our study, the IUDs were
removed laparoscopically (72% of LNG and 58% of copper
cases). Laparotomy was rare in both cohorts (3% and 5%,
respectively). A substantial number of perforated IUDs could
be removed transvaginally via the strings (12% and 21%,
respectively), most commonly in cases of partial perforation.
None of the perforations resulted in serious sequelae, such
as bowel or bladder injury, septicemia or peritonitis.* per 1,000 insertions
Fig. 1. Perforation incidence* with 95% CI stratified by IUD and
breastfeeding at time of insertion.4. Discussion
Perforation rates for the more than 60,000 participating
women were low (1.4 per 1000 insertions in LNG-IUS users/
1.1 per 1000 insertions in copper IUD users), and no serious
complications were associated with any of the 81 perfora-
tions observed. Besides a few partial perforations and
embedded IUDs, the vast majority of these perforations
were complete perforations.
The risk of perforation reported here is within the range
previously observed (0.3 to 2.6 per 1000 insertions). Using
prescription event monitoring (PEM) data, Harrison-Wool-
rych found 0.3 per 1000 insertions for LNG-IUS and 0.6 for
copper IUD users at time of insertion [2]. Kaislasuo et al.
found 0.4 per 1000 insertions for both types of IUD in a
retrospective population-based registry study [4]. Another
study of copper IUD users reported a perforation risk of 2.2
per 1000 insertions [1]. Zhou et al. found an LNG-IUS
perforation incidence of 0.9 per 1000 insertions in a New
Zealand population using PEM data [6], and van Houden-
hoven et al. reported 2.6 for a Dutch population [5]. Because
our study had a large patient base, used prospective sampling
directly from the population and had the greatest depth of
information regarding potential confounding factors, the risk
estimates found here may be regarded as a more robust and
current estimate.
The strongest risk factors for uterine perforation were
breastfeeding at time of insertion and a time since last
delivery of less than 36 weeks. These two factors were
associated with a similar risk increase. Heartwell et al. found
a 10-fold increase in perforation risk for women breastfeed-
ing at the time of insertion but could find no risk differences
for lactating women who had delivered less than 2 months
before IUD insertion compared to more than 2 months. The
authors concluded that breastfeeding rather than time since
last delivery is associated with perforation risk [7].
In most cases of perforation in our study, the IUDs were
removed by laparoscope. This finding corresponds with the
results of other studies. For example, Van Grootheest reportsthat laparoscopy was used in 70% of perforation cases with
known IUD removal methods [11].
Relative risk estimates in observational studies that are
close to unity do not allow differentiation between causation,
bias and confounding [12,13]. In general, it is very difficult to
interpret a relative risk of two or less in such research [14–18].
In seeking to address these difficulties, the EURAS-IUD
study combines several methodological strengths that
contribute to the validity of the results: (a) a prospective,
comparative cohort design; (b) detailed information on
potentially important confounders relevant for the final
statistical models (e.g., breastfeeding status, date of last
delivery); (c) validation of outcomes of interest;
(d) comprehensive follow-up procedure and very low loss
to follow-up to minimize underreporting; (e) a study
population representative for IUD users under routine
clinical conditions and (f) supervision by an independent
Safety Monitoring and Advisory Council as well as scientific
independence from the study funder.
In addition to these methodological strengths, special
attention was paid to typical biases. The approach used in the
EURAS-IUD study probably means that selection bias was
not a major issue. Participation by gynecologists, midwives
and specialized clinics yielded a representative mix of those
who prescribe and insert IUDs. Enrollment bias is also
unlikely to have substantially affected the results. Sites
consecutively enrolled patients who were willing to
participate and who fulfilled the other eligibility criteria.
In order to reduce channeling (referral) bias, factors
associated with the selection of LNG versus copper IUDs, and
also with any of the study outcomes of interest, were measured
at baseline and accounted for in multivariate analyses.
A low overall loss to follow-up rate of 2% was achieved,
in part due to the advantageous study design that enabled
follow-up with the study participants to be maintained even
if they did not return to the center that enrolled them. In
Table 2
Perforation incidencea and RRs stratified by breastfeeding status and time
since last delivery interval
Time since last delivery Breastfeeding
Yes No RR (95% CI)
≤36 weeks 5.6 (3.9–7.9) 1.7 (0.8–3.1) 3.3 (1.6–6.7)
N36 weeks 1.6 (0.0–9.1) 0.7 (0.5–1.1) 2.2 (0.3–16.3)
RR (95% CI) 3.4 (0.5–24.8) 2.3 (1.1–4.7)
a Per 1000 insertions.
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adverse events (SAEs) could have occurred in those patients
who were lost to follow-up because significant events (e.g.,
pregnancy) could have been the reason for the break in
contact with the investigators.
Misclassification bias probably had no substantial impact
on the results given that precise information on the exposure
and the outcomes of interest was available. By contrast, it is
impossible to exclude diagnostic bias. Clinical symptoms of
perforations cover the spectrum from complete absence or
unspecific, slight symptoms to prominent symptoms
[1,5,7,11]. Increased awareness of perforation risks among
LNG-IUS users, especially after a warning letter was issued in
Germany during the early recruitment phase, might have led to
more intensive diagnostic scrutiny and therefore to more
detected perforations, especially asymptomatic ones. This
potential bias could have led to an overestimation of the
relative risk for the LNG-IUS cohort compared to the
copper cohort.
During the study period, no LNG-medicated IUDs
releasing less than 20 mcg LNG daily were on the market in
the participating countries. Therefore, only limited inferences
to LNG containing IUDs with a daily release rate of less than
20 mcg LNG can be made based on these study results.5. Conclusion
No substantial difference in uterine perforation risk was
evident between LNG-IUSs and copper IUDs during routine
clinical use. Breastfeeding and proximity to a recent
delivery (up to 36 weeks) were both independently
associated with an increased risk of uterine perforation.
The presence of these two factors in combination was
associated with an additive increase; however, even among
women with both of these risk factors, perforation remainsTable 3
Perforation incidence stratified by experience of inserting clinician
IUD
insertions
per year
LNG IUS Copper IUD
N Incidencea 95% CI N Incidencea 95% CI
b50 36 1.9 (1.3–2.56) 15 1.5 (0.8–2.5)
≥50/year 21 1.1 (0.7–1.7) 3 0.6 (0.1–1.7)
Unknown 4 0.8 (0.2–2.1) 2 0.6 (0.1–2.3)
a Per 1000 insertions.rare. From a public health perspective, the most important
finding may be the rarity of perforation and the absence of
serious sequelae if perforation occurred.References
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